Sleep and mental disorders …

Laura Palagini MD PhD

Sleep Disorders

Updated 09.13.2024
Released 09.09.1993
Expires For CME 09.13.2027

Sleep and mental disorders

Author: Laura Palagini MD PhD

See Contributor Disclosures

Editor: Antonio Culebras MD FAAN FAHA FAASM

Sleep and mental disorders

In This Article

Quick Link

Introduction

Overview

The author reviews the role of sleep symptomatology in psychiatric disorders and sleep conditions that are associated with psychiatric disorders, including affective, anxiety, and psychotic disorders. Sleep disturbances are common in individuals who are experiencing psychiatric illness and are included in the diagnostic criteria of many of the affective and anxiety disorders. Sleep symptoms may hinder response to treatment and frequently persist after treatment of psychiatric conditions, increasing the risk of relapse or preventing full remission. Thus, clinical attention to sleep disturbances during acute and maintenance treatment of psychiatric conditions is important. Many sleep disorders, especially insomnia and circadian sleep disorder, are considered precipitating and perpetuating risk factors for psychiatric conditions (65). In this article, the author discusses the complex and bidirectional relationship between sleep disturbances and mental conditions. The author discusses general treatments for the management of sleep disturbances experienced in the context of psychiatric illness, including cognitive behavioral therapy for insomnia and its effects on insomnia comorbid with psychiatric conditions. More recently, data support the digital administration of cognitive behavioral therapy for insomnia when appropriate. Novel medications that target orexin are now being used as alternatives to more conventional agents.

Key points

	• Sleep problems and mental disorders can be complex and bidirectional comorbid conditions.
	• The presence of sleep disturbance, such as insomnia, can predispose, precipitate, and complicate the clinical course of patients with psychiatric illness.
	• Effective treatment of sleep disturbance comorbid with psychiatric illness can be accomplished using both pharmacological and nonpharmacological strategies.
	• Sleep disturbance often persists after successful treatment of depression.
	• Treatment of insomnia comorbid with depression can enhance treatment response to antidepressant medication.

Historical note and terminology

Sleep complaints have long been recognized as common in psychiatric disorders, but scientific study of the relationship between sleep and psychiatric disorders began with the introduction of polysomnography as a research and subsequent clinical tool in the 1960s.

Early sleep studies suggested that nocturnal dreaming was restricted to REM sleep, which had only recently been differentiated from other stages of sleep (23). Due to the centrality of dreams in psychoanalytic theory, psychotic hallucinations were thought to be caused by dreams somehow entering the waking state. However, gross intrusion of REM sleep during daytime hours was not observed in patients with schizophrenia. Similarly, nocturnal REM sleep patterns also did not intrude in patients compared to healthy controls (74; 36).

In the late 1960s, it was discovered that intrusion of REM sleep into waking life in the form of hypnagogic hallucinations, sleep paralysis, and cataplexy occurs in the condition of narcolepsy.

Kupfer first observed that a reduced latency from initial sleep onset to REM sleep onset (REM latency) could be demonstrated in major depression (47). This finding is not unique to depression but also occurs in schizophrenia (88), panic disorder (91), and perhaps other psychiatric illnesses. Sitaram and colleagues first suggested that centrally acting cholinergic agonists could induce short REM latency (83). An abnormal cholinergic mechanism may, therefore, be common to several severe mental illnesses. Much current work focuses on the role of central monoaminergic dysfunction in the pathogenesis of psychiatric disorders and the associated sleep disturbance.

The classification of psychiatric disorders and sleep disorders and their current diagnostic criteria are contained in the fifth edition text revision of the Diagnostic and Statistical Manual of Mental Disorders (04). Sleep conditions are also described in The International Classification of Sleep Disorders: Diagnostic and Coding Manual, 3rd edition (03).

In contrast to the preceding version, the DSM-5 does not distinguish between “primary” and “secondary” conditions. Insomnia is instead characterized by its chronicity (80).

Clinical manifestations

Presentation and course

Sleep complaints are common in general medical, psychiatric, and neurologic clinics. Common sleep symptoms include insomnia or hypersomnia, nightmares, and excessive nighttime movements.

Many psychiatric conditions include sleep-related complaints (see table 1). Patients can present with problems initiating or maintaining sleep, problems with sleep quality (ie, not feeling rested), daytime hypersomnolence or added movements, or sleep behaviors.

Table 1. Psychiatric Disorders with Sleep Symptoms

Class	Psychiatric disorders	Sleep complaints	Observed changes in sleep architecture
Mood disorders	Major depressive disorder	Hypersomnia, insomnia, circadian early phase	Prolonged sleep latency, increased REM density
Mood disorders	Bipolar affective disorder	In mania: decreased need for sleep, insomnia circadian delayed phase In depression: insomnia hypersomnia, circadian delayed and irregular phases, nightmares	Reduced total sleep time; shortened REM latency
Anxiety and related disorders	Generalized anxiety disorder	Insomnia, poor sleep quality	Increased sleep latency, decreased sleep continuity
	Panic disorder	Insomnia, nighttime awakenings	Non-REM panic attacks; longer sleep latency, reduced total sleep time, reduced sleep efficiency
	Separation anxiety disorder	Difficulty sleeping without attachment figure nearby	Insufficient data
	Social anxiety	Insomnia	Insufficient data
	Posttraumatic stress disorder	Insomnia, nightmares	Reduced sleep continuity, less sleep depth, and changes in REM sleep
	Acute stress disorder	Insomnia, nightmares	Insufficient data
	Adjustment disorders	Insomnia, poor sleep quality	Insufficient data
	Obsessive-compulsive disorder	Insomnia, late chronotype, late circadian phase	Insufficient data
Psychotic disorders	Schizophrenia	Insomnia, hypersomnia, circadian delayed or irregular phases	Reduced sleep depth and sleep continuity
	Schizoaffective disorder	Decreased need for sleep/total sleep time with mania	Insufficient data
Substance use disorders	CNS depressants (alcohol, opiates, sedative-hypnotics) intoxication and with chronic use	Insomnia, hypersomnia (depending on pattern of use and time from last dose)	Insufficient data
Substance use disorders	CNS stimulants (cocaine, amphetamines)	Insomnia/hypersomnia, (depending on pattern of use)	Insufficient data
Trauma-based disorders	Posttraumatic stress disorder	Insomnia, nightmares	Reduced sleep continuity, less sleep depth, and changes in REM sleep
	Acute stress disorder	Insomnia, nightmares	Insufficient data
	Adjustment disorders	Insomnia, poor sleep quality	Insufficient data
Neurodevelopmental disorders	Autism spectrum disorder	Insomnia, poor sleep quality, irregular and delayed circadian phases	Reduced sleep efficiency, decreased REM and slow wave sleep duration
Neurodevelopmental disorders	Attention deficit and hyperactivity disorder	Insomnia, sleep-disordered breathing and restless legs syndrome/periodic limb movements, treatment-related insomnia, delayed circadian phases	Insufficient data
Neurocognitive disorders	Alzheimer disease and other dementias	Abnormal sleep-wake cycles, insomnia hypersomnia, irregular circadian phases	Abnormal circadian rhythms (day/night reversal), fragmented sleep
Neurocognitive disorders	Diffuse Lewy body dementia and Parkinson disease	Movements during sleep, acting out dreams	REM sleep behavior disorder
Disorders of consciousness	Delirium	Abnormal sleep-wake cycles	Abnormal circadian rhythm, high arousal and awakening index, reduced slow wave sleep and REM sleep

Mood disorders.

Depression. Sleep disturbances (insomnia or hypersomnia) and fatigue are among the diagnostic criteria for major depressive episodes (04). Insomnia is considered an independent risk factor and plays an important role in relapses and recurrences, as it is considered an early sign occurring before both depressive and manic episodes (40; 65). A study of more than 3700 adults with major depressive disorder found that nearly 85% of patients reported symptoms of insomnia (85). Twenty-seven percent of patients reported experiencing all 3 of the major types of insomnia (sleep-onset, mid-nocturnal, and early morning insomnia), with mid-nocturnal insomnia being the most commonly reported type. In a large, community-based cohort study of elderly persons, both short-duration (less than 6 hours per night) and long-duration (9 or more hours per night) sleepers were more likely to have a depressive disorder, including major depressive disorder, minor depressive disorder, or dysthymia, than those sleeping 7 to 8 hours per night (92). Depressed patients also spent more time in bed than those without depression in this study. The severity of illness, cognitive impairments, feelings of hopelessness, lack of resilience, higher likelihood of substance abuse, aggressive and impulsive behavior, difficulties regulating emotions, and increased risk of suicide have all been linked to insomnia (62; 64; 65). In addition, insomnia is associated with a more challenging course and lower response rates to antidepressant treatment in mood disorders (82). Circadian rhythm dysregulation is also typical of depression, especially in the early phases, which are often combined with insomnia and hypersomnia (35). A recent meta-analysis showed that cognitive behavioral treatment for insomnia (CBT-I), which is the first-line treatment for chronic insomnia (76), is effective in treating insomnia and depressive symptoms when insomnia is comorbid with mood disorders (41).

Globally, data indicate that pharmacological treatment of insomnia in mood disorders can also lead to improvements in insomnia symptoms and potentially even in depressive symptomatology. Among GABAergic compounds, eszopiclone has the most evidence supporting its effectiveness in treating insomnia and depressive symptoms when combined with an SSRI in patients with insomnia and major depression. Five randomized controlled trials involving nearly 2000 patients demonstrated that co-administration with an SSRI led to a quicker onset of antidepressant response and a more significant antidepressant effect (32). Among melatonin receptor agonists, melatonin 2-10 PR could potentially serve as an adjunctive therapy for insomnia symptoms in patients with mood disorders, specifically unipolar or bipolar depression. Combining it with antidepressants may also prove beneficial in alleviating depressive symptoms (66). In general, the results related to the effects of dual orexin receptor agonists (DORAs) on insomnia symptoms in the context of mood disorders are very promising. Specifically, both suvorexant and daridorexant have displayed the potential to improve mood symptoms when used to manage insomnia. Daridorexant, especially, has shown to be effective in alleviating both insomnia and mood symptoms in people with unipolar and bipolar depression and has also had a positive impact on manic symptoms (63). Both suvorexant and daridorexant could be beneficial when switching from or discontinuing benzodiazepines in patients with insomnia and mood disorders (63).

Bipolar affective disorder. Sleep disturbance is a cardinal feature of bipolar disorder and part of the diagnostic criteria. During acute mania, patients exhibit markedly reduced sleep time and report a reduced need for sleep and insomnia (70). Even when euthymic, sleep disturbance is common and may affect daytime functioning, with insomnia, hypersomnia, and circadian rhythm dysregulation (38; 35). Both insomnia and hypersomnia have been reported in patients with bipolar depression (38), together with circadian rhythm alterations. Chronotherapeutics, such as light therapy, melatonin agonists, and CBT-I adapted for bipolar patients, are suggested for sleep disorders in bipolar patients (35).

Schizophrenia. Many patients with psychosis have complaints about their sleep, usually due to a problem of sleep onset and maintenance insomnia. The complaint may also involve unsatisfactory sleep related to fragmentation and schedule changes brought about by acute psychosis. In addition, the persistence of sleep complaints in treated schizophrenia is associated with a greater risk of recurrence of psychotic symptoms after antipsychotic withdrawal (16).

The relationship between insomnia and schizophrenia is often viewed as bidirectional; schizophrenia exacerbates sleep disturbances, whereas insomnia can also conversely worsen schizophrenia symptoms (40). Insomnia might emerge during any stage of the illness, including the prodrome, first episode, acute recurrence, and even during remission stages. Severe insomnia is a hallmark of the prodromal phase of psychosis, and it is also a major risk factor for relapse of psychosis. Sleep disturbances have also been associated with exacerbated symptoms in schizophrenia, particularly positive symptoms, including delusions, hallucinations, disorganized thinking, and behavior, or with negative symptoms and cognitive dysfunctions (65). Addiionally, insomnia is associated with increased suicidal ideation and lifetime suicide attempts in patients with schizophrenia. Growing evidence suggests that insomnia may put individuals at a significantly greater risk of developing psychosis; in particular, the relationship between adolescent insomnia and psychotic-like experiences has been shown (65). Studies have also demonstrated that insomnia experienced in adolescents places these individuals at a clinically high risk of future psychosis. A recent meta-analysis confirmed that the early stage and at-risk population of schizophrenia presents with significant impairments of subjective sleep quality continuity, duration, and initiation. Indeed, more precisely, these patients with clinical ultra-high risk and a first episode of psychosis had a lower sleep quality, shorter total sleep time, lower sleep efficiency, longer sleep onset latency, and longer duration of wake after sleep onset (28).

Anxiety and related disorders. Sleep complaints are common in anxiety disorders. Symptoms of insomnia are reported by more than 75% of patients with generalized anxiety disorder (07). Objective studies suggest that patients with generalized anxiety disorder have decreased total sleep time and increased latency to sleep, which correlates with patient reports of ruminating when trying to fall asleep (21).

Since DSM-III was published, insomnia has been one of the key diagnostic criteria for general anxiety disorder. Available data show that insomnia is associated with increased odds of general anxiety disorder (40). Though scarcely investigated, insomnia has been reported in 15% to 85% of patients with general anxiety disorder among adults and up to 87% in children and adolescents (61). Insomnia is related to general anxiety disorder severity and higher risk of comorbidities, such as depressive symptoms and alcohol use, and with resistance to general anxiety disorder treatments. Different therapeutic approaches have been proposed for insomnia treatment in general anxiety disorder. In particular, CBT-insomnia and eszopiclone, when combined with general anxiety disorder therapy, have been effective in treating both insomnia and general anxiety disorder symptomatology, whereas other therapeutic approaches have been proposed, such as gabapentin, pregabalin, or rTMS (repetitive transcranial magnetic stimulation) in few studies.

Similarly, 70% of patients with panic disorder also report sleep disturbances (59). Patients with panic disorder exhibit increased sleep latency and decreased efficacy, with decreased total sleep time. Patients may experience nocturnal panic attacks that may further disrupt sleep (21). Available data show that insomnia symptoms are associated with increased odds of panic disorder and agoraphobia, and their frequency may range from 12% to more than 80% in patients. There is also support for the link between insomnia and panic disorder severity, which may mediate the link with depression and resistance to panic disorder treatments.

Trauma-based disorders. Up to 90% of patients with posttraumatic stress disorder report problems with sleep (55). Indeed, DSM-5 indicates that insomnia and nightmares are diagnostic features of posttraumatic stress disorder (04). The range of sleep changes after trauma extends beyond nightmares and includes insomnia, frequent awakenings, decreased sleep efficiency, and disruptive sleep behaviors. Conditions such as periodic limb movement disorder and obstructive sleep apnea are frequently comorbid with posttraumatic stress disorder (21; 53). Data showed that insomnia may predict subsequent PTSD (61). A meta-analysis of 75 studies estimated that the prevalence of insomnia in PTSD was 63%. Insomnia may contribute to maladaptive stress and emotional responses in PTSD and may complicate its trajectory, increasing the risk of depression, substance use disorder, or suicidal risk. Standard PTSD treatments may decrease insomnia symptoms, but residual insomnia is frequent. Intervention targeting trauma-specific insomnia produces significant short-term effects, including substantial reductions in PTSD symptoms and insomnia severity.

Cognitive behavioral therapy combined with imagery rehearsal therapy or eszopiclone as adjunct therapies resulted in the most effective treatments for insomnia in PTSD (61). Insomnia is now considered a risk factor for obsessive-compulsive disorder, including the perinatal period and the pandemic episodes. Insomnia is frequent in patients with obsessive-compulsive disorder and may affect 30.8% to 70% of them. Insomnia was most related to obsessive-compulsive symptoms compared to other sleep disturbances, such as delayed bedtime and nightmares. This relationship was particularly strong between insomnia and the obsessions and unacceptable thoughts domain of obsessive-compulsive disorder and with the severity of obsessive-compulsive disorder. Similar to other anxiety disorders, the therapeutic approach for obsessive-compulsive disorder may improve insomnia symptoms, but a proportion of the patients suffered from residual symptoms of insomnia after treatment. Hence, a specific insomnia approach has been suggested for obsessive-compulsive disorder.

Neurodevelopmental disorders.

ADHD. Parents commonly report sleep problems in their children with attention deficit hyperactivity disorder. Compared with controls, children with the combined type of ADHD have significantly greater difficulties with enuresis, decreased total sleep time, and increased sleep latency (52). Children with the inattentive type may sleep more than normal and have greater daytime sleepiness than controls (52). Children with ADHD have more movements in sleep than controls (20). Although sleep disturbances may impact up to 70% of children with ADHD, the relationship is complicated and likely multifactorial. Insomnia and circadian rhythm dysregulation may also affect most adults with ADHD (84). Sleep problems may be part of the ADHD pathology or result from treatment of ADHD with stimulant medications, and comorbid conditions, such as sleep apnea, may mimic or exacerbate ADHD symptoms (90).

Autism. Sleep disturbances are found in over 70% of children with autism. Sleep studies indicate reduced sleep efficiency, less slow wave and REM sleep, and more desaturations (01). Sleep disturbances also affect adults with autism spectrum disorders, and circadian rhythm alterations are aspects of insomnia (12).

Substance use disorders. Systematic and narrative literature reviews suggest that substance use disorders, including alcohol, opioids, cannabis, cocaine, or sedative-hypnotic-anxiolytic drugs, share a bidirectional relationship with insomnia and circadian sleep alterations (72; 34). Insomnia can occur before substance dependence or abuse and be associated with withdrawal and relapse. Furthermore, sleeplessness has been associated with ill physical well-being and may also open the door to other addictive side effects. In addition, insomnia has been associated with numerous adverse outcomes in the general population that may also impact patients with substance use disorders, such as decreased well-being and quality of life, occupational functioning, work performance, increased injuries, and poorer physical and mental health. The prevalence of insomnia varies from 30% to 85% in patients with substance use disorder.

Substances like alcohol, cocaine, and heroin are more frequently used by people with insomnia than by people who are generally well-rested. Self-medication attempts can be made to facilitate sleep or reduce the physical and emotional burden resulting from sleep difficulties. Often, alcohol is used to initiate sleep. However, chronic alcohol use is associated with changes in sleep onset and maintenance (10). Complaints of hypersomnia, fragmented sleep/wake cycle, and parasomnias may also occur. Alcohol use disorder is also associated with obstructive sleep apnea. Independent of other factors, insomnia is also a predictor of relapse to alcoholism (10; 15). The duration and quality of sleep are greatly impacted by persistent drug use, and these detrimental effects can also be observed during withdrawal. The effect is dose-dependent, but most drugs alter sleep duration at various stages or the timing of REM and NREM sleep cycles (72; 34).

Prognosis and complications

Sleep disturbances complicate the clinical course of psychiatric disorders. They are associated with poor response to psychotherapy and pharmacotherapy for depression (24; 89; 11; 78; 65) and negatively impact functioning in posttraumatic stress disorder (18; 46). Long (10 or more hours) and short (6 or fewer hours) sleep duration is associated with persistence of anxiety and depression over a 2-year period (93). Insomnia, nightmares, and other sleep disturbances are associated with an increased risk for suicidal ideation, suicide attempts, and completed suicide (68). Treatment of the psychiatric disorder does not always lead to improvements in sleep, as observed in studies of patients with mental comorbidities. Indeed, insomnia is the most commonly reported residual symptom of depression (42). Individuals who report residual sleep disturbances following remission of depression have a poorer quality of life (49) and an increased risk for relapse (27; 26). In these cases, sleep disturbance may persist with the development of perpetuating factors such as substance abuse, poor sleep hygiene, or as a consequence of the medications used to treat the psychiatric disorder. Therefore, independent treatment of sleep disturbance is warranted for some patients, particularly those whose sleep problems persist after their psychiatric condition has remitted.

Importantly, sleep disorders such as insomnia (79; 65), sleep-disordered breathing (95), circadian rhythm dysregulation, and nightmares can be successfully treated in individuals with psychiatric illness (35). A major complication of sleep disorders associated with psychiatric illness is a missed diagnosis of a treatable but comorbid organic condition such as obstructive sleep apnea. If the psychiatric diagnosis is pursued alone, a "refractory" case results, leaving the undiagnosed organic pathology to worsen. Similarly, patients presenting with insomnia should be screened for other conditions such as anxiety, depression, and trauma-based disorders as well.

Clinical vignette

JW, a single, 25-year-old female with bipolar type I disorder, had been relatively stable for 3 years on a regime of lithium 600 mg twice daily and Ambien (zolpidem) 10 mg at bedtime. She had not had a distinct mood episode since her last episode of bipolar mania 3 years prior. She obtained 7 to 8 hours of sleep at night and was satisfied with her job as a respiratory therapist working for a durable medical equipment company.

After the company went out of business, JW took a job as a sleep technician at a growing sleep disorders center. The new job involved working 8 pm to 6 am Tuesday through Friday. JW could only sleep 5 to 6 hours after her shift, even with the aid of zolpidem. She slept about 7 hours on nights she was not working.

Three days before presentation, JW felt unusually energized as she was finishing her shift. She drove home and spent the next 16 hours cleaning her house from top to bottom. JW then slept for an hour and went to a dance club. She left the dance club when it closed at 3 am and returned to her house, where she slept for 2 hours. She exercised extensively the next day and showed up at the sleep center that night. She told her coworkers she was there because she was now the owner of the sleep center, and she wanted to make sure they were doing their jobs right. She was talking rapidly and pacing. JW became agitated when the other sleep technicians refused to take orders from her. The medical director was called. He, with great difficulty, was able to convince her to go to the emergency room. The medical director and a technician drove her to the emergency room, where treatment was begun for a manic episode.

Comment. JW developed a manic episode with symptoms of grandiosity, decreased need for sleep, rapid speech, and increased goal-directed activity. A change in sleep habits can precipitate a bipolar mood episode. Night work and shift work have a destabilizing influence on bipolar disorder.

Biological basis

Etiology and pathogenesis

The etiology of sleep abnormalities in psychiatric disorders is believed to be bidirectional.

Genetic vulnerability for psychiatric disorders and insomnia or circadian sleep dysregulation may overlap. There is emerging evidence for an insomnia-specific polygenic effect on anxiety-mood disorder vulnerability and of a circadian clock gene mutation effect on mood disorder vulnerability (65).

Neuroanatomical circuitry involved in insomnia and circadian rhythm dysregulation may contribute to psychopathology. Accumulating neuroanatomical findings suggest there is likely overlap between circuitries of sleep regulation, anxiety, and mood. Although sleep is critical to the development of these neuroanatomical areas for their plasticity and synaptic balance during adult life (02), insomnia has been related to maladaptive neuroplasticity in both neurodevelopment and adult life. This may lead to impaired emotional, immune, and endocrine pathways (62; 67). Benca and colleagues have reviewed polysomnographic findings in psychiatric disorders (08). Patterns in depression consist of disturbances in sleep continuity (increased latency, decreased sleep efficiency, increased awakenings with early morning awakenings), abnormal distribution of slow-wave sleep, and abnormalities of rapid eye movement sleep (reduced REM latency, abnormal distribution of REM sleep with increased REM percentage of total sleep time, and increased REM density). High-density electroencephalography has shown that females with depression have increased slow-wave activity in bilateral prefrontal regions relative to healthy controls, whereas there are no differences in slow-wave activity between depressed males and healthy controls (69). Continuity disturbances tend to parallel the severity of depression, whereas reduced REM latency and slow-wave sleep tend to persist during remission. In anxiety disorders, the most common finding is sleep continuity disturbance, although inconsistent abnormalities of REM sleep are prominent in studies of posttraumatic stress disorder. Patients with alcohol use disorder display sleep continuity disturbances, decreased slow-wave sleep, and decreased REM sleep, and disturbances may persist after years of abstinence. The presence of insomnia is associated with higher craving for alcohol, which is reduced with sleep aids (39). The sleep patterns of schizophrenia are characterized by decreased REM latency, decreased stage 4 or slow-wave sleep, and sleep continuity abnormalities. Polysomnographic studies of unmedicated manic patients have found shortened total sleep time, shortened REM latency, and increased time awake in bed (70).

There is strong evidence for muscarinic (cholinergic) involvement in short REM sleep latency. Patients with depression and schizophrenia show a substantial shortening of the already short REM sleep latency when given muscarinic agonist drugs (77; 81). Levels of an abnormal plasma cholinesterase isozyme in patients with schizophrenia correlate with REM latency (44). A polymorphism of the muscarinic receptor 2 gene was found to be associated with major depression in women (19).

Similar sleep alterations have been found in insomnia, presenting a link with the psychopathology of REM sleep instability (75). Because increased REM pressure is a transdiagnostic phenomenon across various mental disorders, such as depression, schizophrenia, borderline personality disorder, and substance dependency, this has been hypothesized as the pathway linking insomnia to mental disorders (75).

Neuromodulators of sleep regulation or psychopathology. Orexin dysfunction has been hypothesized to be implicated in the hyperactivation of arousal-promoting systems in insomnia and pathophysiology (13). Several other potential mechanisms through which sleep alterations might increase the risk or perpetuation of mental disorders have been hypothesized. Insomnia, sleep loss, and circadian sleep dysregulation may be linked to stress and hyperactivation of the inflammatory system, monoamine neurotransmission alterations, hypothalamic-pituitary-adrenal-axis abnormalities, glutamatergic and orexinergic dysregulation, brain neurotrophic factors alterations, and brain neuroplasticity dysfunction (70; 65).

Studies utilizing functional brain imaging have shown an overlap between abnormal regions involved in psychiatric disorders and those known to be involved in sleep regulation. Abnormalities of central monoaminergic systems, especially serotonin, have been implicated in the pathogenesis of depression, and these systems play critical roles in sleep regulation (48; 02).

Differential diagnosis

Periodic limb movement disorder and obstructive sleep apnea are more common in patients with posttraumatic stress disorder than in the general population (50). Obstructive sleep apnea can produce severe daytime somnolence and cognitive impairment, which together resemble psychomotor retardation, a diagnostic feature of both depression and bipolar disorder or poor concentration with ADHD. Symptoms of sleep apnea, including snorting or stopping breathing while asleep, are associated with depressive symptoms (96).

Narcolepsy shares features with several psychiatric syndromes. These shared features, especially hallucinations, can be a source of diagnostic confusion. Most patients with narcolepsy have full insight into their hypnagogic hallucinations. They are unusually realistic 3-dimensional visual hallucinations and often surface with multimodal sensory features (sound, touch, taste, smell). At times, they are overlaid on perceptions of the actual environment, giving rise to delusional interpretations of ghosts and the like (30). Hallucinations in schizophrenia can include visual components but more commonly involve disembodied voices that converse with the patient, comment about him or her, or give instructions. Delusions tend to be elaborate and highly implausible, whereas psychotic patients with narcolepsy tend to restrict their delusions to a simple explanation of the repetitive hallucinations ("secondary delusions"). Occasionally, patients presenting with what appears to be hypomania (irritability, hyperactivity, rapid speech, etc.) are found to have narcolepsy after sleep laboratory testing. Such patients may never have regarded themselves as “sleepy.”

Sleep disturbances may coexist with psychiatric disorders and medical disorders, including pain disorders, prostatic hypertrophy, nocturnal asthma, cardiopulmonary disease, and hyperthyroidism. Medications used to treat psychiatric disorders, such as SSRIs, can disrupt sleep either directly through their activating effect or indirectly through the worsening of restless legs syndrome or periodic limb movement disorder.

Diagnostic workup

Patients presenting with sleep complaints should receive a full evaluation with thorough medical and psychiatric review of systems. A careful sleep history is necessary to understand sleep patterns and any behaviors that may be contributing (ie, using full spectrum screens before bed, caffeine, and alcohol and other substance use, including over-the-counter medications).

A physical examination is important in all patients to evaluate for any signs or symptoms of any condition that may be associated with changes in sleep as primary sleep disorders can mimic some psychiatric symptoms or be co-occurring.

Daily sleep logs or diaries maintained over a 1- to 2-week period can aid in diagnosing insomnia as suggested by subjective report of difficulty falling asleep or maintaining sleep in conjunction with daytime impairments due to poor sleep. Individuals with bipolar disorder who report difficulty falling or staying asleep or short sleep duration (eg, less than 6 hours) without daytime impairment or excessive daytime sleepiness may be experiencing mania or hypomania. Sleep logs should correlate with presentation of pressured speech, expansive affect, increased goal-directed activity, and other symptoms that are part of mania. Sleep logs should be used to evaluate circadian sleep alterations in patients with mental disturbances because they are so frequent. A special question on dreaming activity should be included in mental disturbance examinations because bad dreams or nightmares may be often present in mental disturbances.

A polysomnogram and multiple sleep latency test may be indicated if a specific sleep disorder, such as narcolepsy, periodic limb movement disorder, or sleep apnea, is suspected or when the sleep disturbance persists despite treatment of the underlying psychiatric disorder. Although some psychotic patients may not easily comply with sleep laboratory procedures, most such patients can be studied if given more attention by the technicians.

Management

The management of sleep disturbance in psychiatric disorders depends on the type of sleep disorder. Cognitive and behavioral therapy for insomnia is considered the first line of treatment, and data sustain its efficacy when insomnia is comorbid with mental disturbances (Hertenstein et a 2022). Cognitive behavioral therapy for insomnia (CBTi) is a highly effective nonpharmacological treatment option for insomnia (54). Typically, short-term (4 to 8 sessions) cognitive behavioral therapy for insomnia integrates cognitive and behaviorally-based treatment modalities to target the factors believed to perpetuate insomnia. The behavioral components include sleep restriction, stimulus control procedures, and relaxation training. The cognitive component of therapy consists of educating the patient about the role of negative sleep-related thoughts in perpetuating sleep problems. Patients are also educated about sleep hygiene, which refers to daytime habits (eg, exercise, napping, substance use close to bedtime) and environmental circumstances (eg, temperature regulation, bed comfort) that can help or hinder sleep.

Treatment of insomnia using cognitive behavioral therapy for insomnia improves sleep in patients with comorbid psychiatric conditions, including depression, posttraumatic stress disorder, and alcoholism (05; 51; 86). For individuals with depression, it enhances treatment response to antidepressant medications and improves remission rates (51).

Internet-based cognitive behavioral therapy for insomnia has been studied and found to be an effective treatment for insomnia (31). Unguided, digitally-delivered cognitive behavioral therapy for insomnia has effects that persist up to 18 months after intervention (94). Treatment of insomnia with computer-based cognitive behavioral therapy for insomnia was found to reduce incident depression at 1-year follow-up (17).

Drugs indicated for the treatment of insomnia include benzodiazepines and benzodiazepine receptor agonists, also known as Z Drugs.

Pharmacological therapy beyond agents used to treat the underlying psychiatric disorder may benefit some patients. Medications for sleep can be divided into GABAergic medications, melatonin/agonists, sedating antihistamines, and, more recently, orexin-antagonists.

Benzodiazepines or benzodiazepine receptor agonists, such as zolpidem or zaleplon, may be used, preferably on a short-term or intermittent basis. They should be avoided in any patients who have a history of alcohol or sedative/hypnotic use disorders, the elderly, or patients with respiratory disease. The benzodiazepine receptor agonist eszopiclone has been studied in patients with coexisting insomnia and major depressive disorder. During an 8-week trial involving this population, eszopiclone combined with fluoxetine improved wake time after sleep onset, total sleep time, sleep latency, and depression rating scale scores compared to patients taking fluoxetine alone (32). In addition to being studied in patients with coexisting major depressive disorder and insomnia, eszopiclone has also been shown to be an effective hypnotic in patients with generalized anxiety disorder and coexisting insomnia (71). When administered with an SSRI, eszopiclone significantly improved insomnia and depressive symptoms in patients with major depression, whereas zolpidem improved insomnia symptoms but not mood symptoms. Treatment of insomnia with these agents beyond 3-4 weeks is not endorsed in Europe by drug regulating authorities because of the related adverse events and the emergence of tolerance/rebound and abuse/dependency. The hypnotic eszopiclone has received an extended use (8 to 12 weeks) approval.

In Europe, a prolonged-release formulation of melatonin 2 mg can be prescribed for long-term (3 months) treatment of insomnia in patients over 55 years of age. These were studied in patients with bipolar and unipolar depression. For unipolar or bipolar depression, melatonin may be recommended as an adjuvant treatment for insomnia symptoms. Regarding the melatonin formula, prolonged release at 2 to 10 mg should be preferred for insomnia treatment in mood disorders. Higher doses of melatonin (more than 2 mg prolonged-release) might be needed in mood disorders compared to patients with insomnia disorder in relation to polymorphisms of circadian clock genes or to mutations in melatonin pathway-related genes and receptors that characterize patients with mood disorders. Conflicting results are presented for ramelteon (56).

Orexin receptor antagonists (DORAs) have been proposed for the treatment of depression, showing antidepressant-like activity in animal models (13). In humans, the efficacy of suvorexant has been investigated in different studies in patients with insomnia. A significant improvement in self-reported sleep quality, duration, and continuity was found after 1 week of treatment with suvorexant 15 mg or 20 mg. Similarly, in three studies, the DORA daridorexant 50 mg was shown to also improve insomnia and mood symptoms in patients with unipolar and bipolar depression treated with SRRIs and mood stabilizers (63).

In addition, it would also be helpful to address circadian rhythm alterations that are often associated with insomnia in mood disorders. In this framework, the importance of integrating insomnia treatment with chronotherapeutics in mood disorders emerges (35). These interventions include CBT-I, which may be a particularly useful intervention to stabilize sleep and circadian rhythms even in bipolar depression, along with light therapy and sleep deprivation. The maintenance of a stable sleep/wake cycle and regularization of the circadian rhythm are key components of effective psychotherapy for bipolar disorder. Daily sleep diaries can be helpful to track the sleep/wake cycle in patients with bipolar disorder. Interpersonal and social rhythm therapy is most effective for mood episode prophylaxis in the maintenance phase of bipolar disorder and in individuals without significant medical comorbidity or anxiety (33). A pilot study found that “dark therapy,” which is 14 hours of enforced darkness from 6 pm to 8 am for 3 consecutive nights, was a useful add-on therapy for inpatients with bipolar mania (06).

Continuous positive airway pressure is the gold-standard treatment for sleep-disordered breathing. Treatment of sleep-disordered breathing using continuous positive airway pressure in individuals with depression is associated with a reduction in depression symptoms, even in patients whose depression was resistant to pharmacotherapy (37).

There is growing evidence that CBT-I may reduce anxiety symptoms in healthy individuals and those experiencing anxiety/anxiety-related disorders (41).

In the short-term, pharmacological options include the use of benzodiazepines and non-benzodiazepine allostatic modulators of the GABA receptor with conflicting results except for eszopiclone. Randomized clinical trials were conducted in individuals with general anxiety disorder and PTSD. Studies have shown that the co-administration of eszopiclone and an SSRI was effective in insomnia and anxiety symptoms. Melatonin has not been evaluated as a treatment for insomnia in anxiety disorders, including generalized anxiety disorder, obsessive-compulsive disorder, social phobia, specific phobia, or posttraumatic stress disorder. DORAs are emerging in anxiety and related disorders, and both suvorexant and daridorexant were shown to improve insomnia and anxiety symptoms as well (61; 63).

Administration of prazosin, an alpha-1 adrenergic antagonist, has shown some evidence to support its use to prevent nightmares at doses of 1 to 20 mg/day in several small studies; it also decreased the intensity and frequency of posttraumatic stress disorder-related nightmares and improved subjective sleep quality (25). A study did not show an effect of prazosin to combat posttraumatic stress disorder (73). Imagery rehearsal therapy, targeting nightmares and sleep disturbance in individuals with posttraumatic stress disorder, improves sleep, nightmares, and daytime functioning (45; 22; 14). Combining imagery rehearsal therapy and cognitive behavioral therapy for insomnia improves sleep quality more than imagery rehearsal alone (14).

Onemeta-analysis demonstrated that cognitive behavioral therapy is effective for the treatment of insomnia in patients with clinical diagnoses of different psychiatric disorders, including schizophrenia. Indeed, in most patients with schizophrenia and insomnia, the usual treatment is the supplementation of antipsychotics with benzodiazepines or Z-drugs. However, prolonged benzodiazepine administration has been associated with various adverse reactions, including sedation and cognitive impairment, and the effects of antipsychotics on sleep are not well established. Therefore, the established pharmacological pathways for the treatment of insomnia in schizophrenia are still under evaluation. Some evidence suggests melatonin 2 mg prolonged-release administration for insomnia treatment in schizophrenia. Because melatonin may have chronobiotic properties, it may be useful in schizophrenia. Data on insomnia treatment suggest that the prolonged-release melatonin formulation at 2 mg is effective in improving sleep symptoms in schizophrenic patients (66). The interaction between orexin and dopaminergic neurons in the midbrain, thalamocortical area, and amygdala suggests a potential role for orexinergic neurons in modulating dopaminergic neurons. The preclinical evidence indicates a deficiency of orexins in schizophrenia, suggesting that DORAs may be useful in the management of insomnia associated with schizophrenia. Manipulations of sleep can have a positive impact on treating schizophrenia by promoting the restorative effects of sleep on cognition, metabolism, and immune function and by decreasing hyperarousal (13).

The therapeutic approach remains a significant obstacle for insomnia and circadian sleep disorders in the context of substance use disorders. CBT-I is the recommended first-line treatment for combined insomnia and substance use disorder, especially for alcohol use disorder. The treatment options available for insomnia symptoms and disorders in substance addiction are limited, primarily because conventional hypnotics that target benzodiazepine receptors are associated with abuse potential, withdrawal effects, and the potential for overdose.

It has been demonstrated that melatonin supplementation holds significant value in managing sleep and circadian rhythm disorders in these patients, although the current studies are limited. The ability of melatonin to mitigate different aspects of addiction neurobiology has been extensively studied in animal studies. Studies have reported the efficacy of melatonin supplementation in controlling drug-seeking behavior, opiate withdrawal/relapse, behavioral sensitization, sleep regulation, circadian rhythm disorders, and neuroplasticity in brain areas linked to reward and emotion regulation. Although melatonin did not increase the likelihood of discontinuation of benzodiazepine, it did enhance sleep quality, particularly in subjects who continued to utilize benzodiazepine. Prolonged-release melatonin at 2 mg may be useful during benzodiazepine discontinuation and may improve sleep quality during benzodiazepine withdrawal. The use of melatonin in the treatment of sleep disturbances in patients with alcohol use disorder has been discussed in a review (66).

The use of antagonists of orexin receptors is becoming a promising strategy for treating drug addiction (13). Within this framework, animal studies demonstrated that DORAs reduced acute cocaine-induced impulsivity, decreased motivational and hedonic properties of cocaine, reduced relapse from alcohol, and enhanced disrupted sleep in relation to alcohol withdrawal. Several studies regarding this topic are currently underway. Two studies focused on the administration of daridorexant or suvorexant with alcohol use in healthy individuals. In contrast, in another study, suvorexant was administered to individuals with cocaine use disorder in an experimental protocol involving cocaine assumption. Suvorexant (10 mg, 20 mg) increased self-administration of 10 mg/70 kg cocaine and decreased oral temperature but did not significantly alter any other effects of cocaine. DORAs have the potential to emerge as a promising resource in the treatment of drug addiction, as they target both specific mechanisms and comorbid or withdrawal-related sleep problems. However, further research is required to evaluate their efficacy and safety in patients with substance use disorder.

References

01: Aathira R, Gulati S, Tripathi M, et al. Prevalence of sleep abnormalities in Indian children with autism spectrum disorder: a cross-sectional study. Pediatr Neurol 2017;74:62-7. PMID 28739359
02: Aquino G, Benz F, Dressle RJ, et al. Towards the neurobiology of insomnia: a systematic review of neuroimaging studies. Sleep Med Rev 2024;73:101878. PMID 38056381
03: American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual. 3rd ed. American Academy of Sleep Medicine, 2014.
04: American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision TR. Washington, DC: American Psychiatric Association, 2022.
05: Arnedt JT, Conroy D, Rutt J, Aloia M, Brower KJ, Armitage R. An open trial of cognitive-behavioral treatment for insomnia comorbid with alcohol dependence. Sleep Med 2007;8(2):176-80. PMID 17239658
06: Barbini B, Benedetti F, Colombo C, et al. Dark therapy for mania: a pilot study. Bipolar Disord 2005;7(1):98-101. PMID 15654938
07: Belanger L, Morin CM, Langlois F, Ladouceur R. Insomnia and generalized anxiety disorder: effects of cognitive behavior therapy for gad on insomnia symptoms. J Anxiety Disord 2004;18(4):561-71. PMID 15149714
08: Benca RM, Obermeyer WH, Thisted RA, Gillin C. Sleep and psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 1992;49:6511-668. PMID 1386215
09: Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal study of young adults. Biol Psychiatry 1996;39:411-8. PMID 8679786
10: Brower KJ, Aldrich MS, Robinson EA, Zucker RA, Greden JF. Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry 2001;158(3):399-404. PMID 11229980
11: Buysse DJ, Tu XM, Cherry CR, et al. Pretreatment REM sleep and subjective sleep quality distinguish depressed psychotherapy remitters and nonremitters. Biol Psychiatry 1999;45(2):205-13. PMID 9951568
12: Carmassi C, Palagini L, Caruso D, et al. Systematic review of sleep disturbances and circadian sleep desynchronization in autism spectrum disorder: toward an integrative model of a self-reinforcing loop. Front Psychiatry 2019;10:366. PMID 31244687
13: Carpi M, Palagini L, Fernandes M, et al. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: neurological and psychiatric comorbidities. Neuropharmacology 2024;245:109815. PMID 38114045
14: Casement MD, Swanson LM. A meta-analysis of imagery rehearsal for post-trauma nightmares: effects on nightmare frequency, sleep quality, and posttraumatic stress. Clin Psychol Rev 2012;32(6):566-74. PMID 22819998
15: Chakravorty S, Chaudhary NS, Brower KJ. Alcohol dependence and its relationship with insomnia and other sleep disorders. Alcohol Clin Exp Res 2016;40(11):2271-82. PMID 27706838
16: Chemerinski E, Ho BC, Flaum M, Arndt S, Fleming F, Andreasen NC. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr Psychiatry 2002;43(5):393-6. PMID 12216015
17: Cheng P, Kalmbach DA, Tallent G, Joseph CL, Espie CA, Drake CL. Depression prevention via digital cognitive behavioral therapy for insomnia: a randomized controlled trial. Sleep 2019;42(10):zsz150. PMID 31535688
18: Clum GA, Nishith P, Resick PA. Trauma-related sleep disturbance and self-reported physical health symptoms in treatment-seeking female rape victims. J Nerv Ment Dis 2001;189(9):618-22. PMID 11580006
19: Comings DE, Wu S, Rostamkhani M, McGue M, Iacono WG, MacMurray JP. Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Geneti 2002;114(5):527-9.
20: Cortese S, Konofal E, Yateman N, Mouren MC, Lecendreux M. Sleep and alertness in children with attention-deficit/hyperactivity disorder: a systematic review of the literature. Sleep 2006;29(4):504-11. PMID 16676784
21: Cox RC, Olatunji BO. A systemic review of sleep disturbance in anxiety and related disorders. J Anxiety Disord 2016;37:104-29. PMID 26745517
22: Davis JL, Wright DC. Randomized clinical trial for treatment of chronic nightmares in trauma-exposed adults. J Trauma Stress 2007;20(2):123-33. PMID 17427914
23: Dement W, Kleitman N. Cyclic variations in EEG during sleep and their relation to eye movements, body motility, and dreaming. Electroencephalogr Clin Neurophysiol 1957;9:673-90. PMID 13480240
24: Dew MA, Reynolds CF 3rd, Houck PR, et al. Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997;54(11):1016-24. PMID 9366658
25: Dierks MR, Jordan JK, Sheehan AH. Prazosin treatment of nightmares related to posttraumatic stress disorder. Ann Pharmacother 2007;41:1013-7. PMID 17504838
26: Dombrovski A, Cyranowski J, Mulsant B, et al. Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy. Depress Anxiety 2008;25(12):1060-6. PMID 18781665
27: Dombrovski AY, Mulsant BH, Houck PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord 2007;103(1-3):77-82. PMID 17321595
28: Donde C, Jaffiol A, Khouri C, et al. Sleep disturbances in early clinical stages of psychotic and bipolar disorders: A meta-analysis. Aust N Z J Psychiatry 2022;56(9):1068-79. PMID 34971518
29: Dorheim SK, Bondevik GT, Eberhard-Gran M, Bjorvatn B. Sleep and depression in postpartum women: a population-based study. Sleep 2009;32(7):847-55. PMID 19639747
30: Douglass AB, Hays P. Three simultaneous major sleep disorders. Can J Psychiatry 1987;32:57-60. PMID 3815255
31: Espie CA, Emsley R, Kyle SD, et al. Effect of digital cognitive behavioral therapy for insomnia on health, psychological well-being, and sleep-related quality of life: a randomized clinical trial. JAMA Psychiatry 2019;76(1):21-30. PMID 30264137
32: Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006;59:1052-60. PMID 16581036
33: Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005;62(9):996-1004. PMID 16143731
34: Geoffroy PA, Lejoyeux M, Rolland B. Management of insomnia in alcohol use disorder. Expert Opin Pharmacother 2020;21(3):297-306. PMID 31899990
35: Geoffroy PA, Palagini L. Biological rhythms and chronotherapeutics in depression. Prog Neuropsychopharmacol Biol Psychiatry 2021;106:110158. PMID 33152388
36: Gulevich GD, Dement WC, Zarcone VP. All-night sleep recordings of chronic schizophrenics in remission. Compr Psychiatry 1967;8(3):141-9. PMID 6046064
37: Habukawa M, Uchimura N, Kakuma T, et al. Effect of CPAP treatment on residual depressive symptoms in patients with major depression and coexisting sleep apnea: Contribution of daytime sleepiness to residual depressive symptoms. Sleep Med 2010;11(6):552-7. PMID 20488748
38: Harvey AG. Sleep and circadian rhythms in bipolar disorder: seeking synchrony, harmony, and regulation. Am J Psychiatry 2008;165(7):820-9. PMID 18519522
39: He S, Brooks AT, Kampman KM, Chakravorty S. The relationship between alcohol craving and insomnia symptoms in alcohol-dependent individuals. Alcohol Alcohol 2019;42(3):287-94. PMID 31087085
40: Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep Med Rev 2019;43:96-105. PMID 30537570
41: Hertenstein E, Trinca E, Wunderlin M, et al. Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: a systematic review and meta-analysis. Sleep Med Rev 2022;62:101597. PMID 35240417
42: Iovieno N, van Nieuwenhuizen A, Clain A, Baer L, Nierenberg AA. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Depress Anxiety 2011;28(2):137-44. PMID 21284066
43: Jaussent I, Bouyer J, Ancelin ML, et al. Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly. Sleep 2011;34(8):1103-10. PMID 21804672
44: Keshavan MS, Mahadik SP, Reynolds CF 3rd, et al. Plasma cholinesterase isozymes and REM latency in schizophrenia. Psychiatry Res 1992;43(1):23-9. PMID 1438614
45: Krakow B, Hollifield M, Johnston L, et al. Imagery rehearsal therapy for chronic nightmares in sexual assault survivors with posttraumatic stress disorder: a randomized controlled trial. JAMA 2001;286(5):537-45. PMID 11476655
46: Krakow B, Melendrez D, Johnston L, et al. Sleep-disordered breathing, psychiatric distress, and quality of life impairment in sexual assault survivors. J Nerv Ment Dis 2002;190(7):442-52. PMID 12142845
47: Kupfer DJ, Foster FG. Interval between onset of sleep and rapid-eye-movement sleep as an indicator of depression. Lancet 1972;2:684-6. PMID 4115821
48: Leonard BE. Serotonin receptors and their function in sleep, anxiety disorders and depression. Psychother Psychosom 1996;65(2):66-75. PMID 8711084
49: Li SX, Lam SP, Chan JW, Yu MW, Wing YK. Residual sleep disturbances in patients remitted from major depressive disorder: a 4-year naturalistic follow-up study. Sleep 2012;35(8):1153-61. PMID 22851811
50: Maher MJ, Rego SA, Asnis GM. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 2006;20(7):567-90. PMID 16800716
51: Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 2008;31(4):489-95. PMID 18457236
52: Mayes SD, Calhoun SL, Bixler EO, et al. ADHD subtypes and comorbid anxiety, depression, and oppositional-defiant disorder: differences in sleep problems. J Pediatr Psychol 2009;34(3):328-37. PMID 18676503
53: Miller KE, Browllow JA, Woodward S, Gehrman PR. Sleep and dreaming in posttraumatic stress disorder. Curr Psychiatry Rep 2017;19(10):71. PMID 28828641
54: Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999;281(11):991-9. PMID 10086433
55: Neylan TC, Marmar CR, Metzler TJ, et al. Sleep disturbances in the Vietnam generation: findings from a nationally representative sample of male Vietnam veterans. Am J Psychiatry 1998;155(7):929-33. PMID 9659859
56: Norris ER, Karen B, Correll JR, et al. A double-blind, randomized, placebo-controlled trial of adjunctive ramelteon for the treatment of insomnia and mood stability in patients with euthymic bipolar disorder. J Affect Disord 2013;144(1-2):141-7. PMID 22963894
57: O'Brien LM, Bullough AS, Owusu JT, et al. Pregnancy-onset habitual snoring, gestational hypertension, and preeclampsia: prospective cohort study. Am J Obstet Gynecol 2012;207(6):487.e1-9. PMID 22999158
58: Okun ML, Luther J, Prather AA, Perel JM, Wisniewski S, Wisner KL. Changes in sleep quality, but not hormones predict time to postpartum depression recurrence. J Affect Disord 2011;130(3):378-84. PMID 20708275
59: Overbeek T, van Diest R, Schruers K, Kruizinga F, Griez E. Sleep complaints in panic disorder patients. J Nerv Ment Dis 2005;193(7):488-93. PMID 15985844
60: Palagini L, Bramante A, Baglioni C, et al. Insomnia evaluation and treatment during peripartum: a joint position paper from the European Insomnia Network task force "Sleep and Women," the Italian Marcè Society and international experts task force for perinatal mental health. Arch Womens Ment Health 2022a;25(3):561-75. PMID 35419652
61: Palagini L, Cipriani E, Caruso V, et al. Insomnia during the perinatal period and its association with maternal and infant psychopathology: a systematic review and meta-analysis. Curr Psychiatry Rep 2023;25(11):617-41. PMID 37819491
62: Palagini L, Domschke K, Benedetti F, Foster RG, Wulff K, Riemann D. Developmental pathways toward mood disorders in adult life: is there a role for sleep disturbances? J Affect Disord 2019;243:121-32. PMID 30243192
63: Palagini L, Geoffroy P, Alfì G, et al. Insomnia and the orexinergic pathway in the link with psychopathology: effects of DORAs in insomnia comorbid with mental disturbances. Curr Sleep Med Rep 2024a;10:1-13.
64: Palagini L, Geoffroy PA, Riemann D. Sleep markers in psychiatry: do insomnia and disturbed sleep play as markers of disrupted neuroplasticity in mood disorders? A proposed model. Curr Med Chem 2022b;29(35):5595-605. PMID 34906053
65: Palagini L, Hertenstein E, Riemann D, Nissen C. Sleep, insomnia and mental health. J Sleep Res 2022c;31(4):e13628. PMID 35506356
66: Palagini L, Manni R, Aguglia E, et al. International expert opinions and recommendations on the use of melatonin in the treatment of insomnia and circadian sleep disturbances in adult neuropsychiatric disorders. Front Psychiatry 2021;12:688890. PMID 34177671
67: Palagini L, Miniati M, Caruso V, et al. Insomnia, anxiety and related disorders: a systematic review on clinical and therapeutic perspective with potential mechanisms underlying their complex link. Neurosci Applied 2024b;3:103936.
68: Pigeon WR, Pinquart M, Conner K. Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J Clin Psychiatry 2012;73(9):e1160-7. PMID 23059158
69: Plante DT, Landsness EC, Peterson MJ, et al. Sex-related differences in sleep slow wave activity in major depressive disorder: a high-density EEG investigation. BMC Psychiatry 2012;12(1):146. PMID 22989072
70: Plante DT, Winkelman JW. Sleep disturbance in bipolar disorder: therapeutic implications. Am J Psychiatry 2008;165(7):830-43. PMID 18483132
71: Pollack M, Kinrys G, Krystal A, et al. Evaluation of eszopiclone and escitalopram oxalate co-therapy in patients with generalized anxiety disorder and insomnia. Paper presented at: American College of Neuropsychopharmacology; December 2006; Hollywood, Florida.
72: Provencher T, Lemyre A, Vallières A, Bastien CH. Insomnia in personality disorders and substance use disorders. Curr Opin Psychol 2020;34:72-6. PMID 31778972
73: Raskind MA, Peskind ER, Chow B, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med 2018;378(6):507-17. PMID 29414272
74: Rechtschaffen A, Schulsinger F, Mednick SA. Schizophrenia and physiological indices of dreaming. Arch Gen Psychiatry 1964;10:89-93. PMID 14066011
75: Riemann D, Dressle RJ, Benz F, et al. Chronic insomnia, REM sleep instability and emotional dysregulation: a pathway to anxiety and depression? J Sleep Res 2024:e14252. PMID 38811745
76: Riemann D, Espie CA, Altena E, et al. The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023. J Sleep Res 2023;32(6):e14035. PMID 38016484
77: Riemann D, Gann H, Fleckenstein P, Hohagen F, Olbrich R, Berger M. Effect of RS-86 on REM latency in schizophrenia. Psychiatry Res 1991;38:89-92. PMID 1946836
78: Roest AM, Carney RM, Stein PK, et al. Obstructive sleep apnea/hypopnea syndrome and poor response to sertraline in patients with coronary heart disease. J Clin Psychiatry 2012;73(1):31-6. PMID 21903027
79: Sanchez-Ortuno MM, Edinger JD. Cognitive-behavioral therapy for the management of insomnia comorbid with mental disorders. Curr Psychiatry Rep 2012;14(5):519-28. PMID 22865156
80: Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest 2014;146(5):1387-94. PMID 25367475
81: Schreiber W, Lauer CJ, Krumrey K, Holsboer F, Krieg JC. Cholinergic REM sleep induction test in subjects at high risk for psychiatric disorders. Biol Psychiatry 1992;32:79-90. PMID 1391297
82: Seow LS, Verma SK, Mok YM, et al. Evaluating DSM-5 insomnia disorder and the treatment of sleep problems in a psychiatric population. J Clin Sleep Med 2018;14(2):237-44. PMID 29394962
83: Sitaram N, Mendelson WB, Wyatt RJ, Gillin JC. The time-dependent induction of REM sleep and arousal by physostigmine infusion during normal human sleep. Brain Res 1977;122:562-7. PMID 191144
84: Spera V, Maiello M, Pallucchini A, et al. Adult attention-deficit hyperactivity disorder and clinical correlates of delayed sleep phase disorder. Psychiatry Res 2020;291:113162. PMID 32554185
85: Sunderajan P, Gaynes B, Wisniewski S, et al. Insomnia in patients with depression: a STARD report. CNS Spectr 2010;15(6):394-404. PMID 20625372
86: Swanson L, Favorite TK, Horin E, Arnedt JT. A combined group treatment for nightmares and insomnia in combat veterans: a pilot study. J Trauma Stress 2009;22(6):639-42. PMID 19908322
87: Swanson LM, Flynn H, Adams-Mundy JD, Armitage R, Arnedt JT. An open pilot of cognitive-behavioral therapy for insomnia in women with postpartum depression. Behav Sleep Med 2013;11(4):297-307. PMID 23216373
88: Tandon R, Shipley JE, Taylor S, et al. Electroencephalographic sleep abnormalities in schizophrenia. Arch Gen Psychiatry 1992;49:185-94. PMID 1348923
89: Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy. The role of abnormal EEG sleep profiles. Am J Psychiatry 1997;154(4):502-9. PMID 9090337
90: Tsai MH, Hsu JF, Huang YS. Sleep problems in children with attention deficit/hyperactivity disorder: current status of knowledge and appropriate management. Curr Psychiatry Rep 2016;18(8):76. PMID 27357497
91: Uhde TW, Roy-Byrne P, Gillin JC, et al. The sleep of patients with panic disorder: a preliminary report. Psychiatry Res 1984;12(3):251-9. PMID 6593756
92: van den Berg JF, Luijendijk HJ, Tulen JH, et al. Sleep in depression and anxiety disorders: a population-based study of elderly persons. J Clin Psychiatry 2009;70(8):1105-13. PMID 19607762
93: van Mill JG, Vogelzangs N, van Someren EJ, Hoogendijk WJ, Penninx BW. Sleep duration, but not insomnia, predicts the 2-year course of depressive and anxiety disorders. J Clin Psychiatry 2014;75(2):119-26. PMID 24345733
94: Vedaa O, Hagatun S, Kallestad H, et al. Long-term effects of an unguided online cognitive behavioral therapy for chronic insomnia. J Clin Sleep Med 2019;15(1):101-10. PMID 30621837
95: Wells RD, Freedland KE, Carney RM, Duntley SP, Stepanski EJ. Adherence, reports of benefits, and depression among patients treated with continuous positive airway pressure. Psychosom Med 2007;69(5):449-54. PMID 17556641
96: Wheaton AG, Perry GS, Chapman DP, Croft JB. Sleep disordered breathing and depression among U.S. adults: National Health and Nutrition Examination Survey, 2005-2008. Sleep 2012;35(4):461-7. PMID 22467983

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Laura Palagini MD PhD

Dr. Palagini of the University Hospital of Pisa, Italy, received consultancy royalties from Bruno SPA, Fidia, Idorsia, Neuropharmed, Pfizer, and Sanofi.
See Profile

Editor

Antonio Culebras MD FAAN FAHA FAASM

Dr. Culebras of SUNY Upstate Medical University at Syracuse has no relevant financial relationships to disclose.
See Profile

Former Authors

Alan B Douglass MD
Stephen P Duntley MD
Michael J Rack MD
Leslie M Swanson PhD
Rebekah Jakel MD PhD

Patient Profile

Age range of presentation: 6 to 65+ years
Sex preponderance: Sex preponderance varies for individual conditions discussed.
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Sleep disorder, unspecified: G47.9

Disorders of the sleep-wake schedule: G47.2
ICD-11: Sleep-wake disorders, unspecified: 7B2Z

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Sleep and mental disorders

Associated Disorders

Alcoholism
Anxiety
Bipolar disorder
Depression
Hypersomnia
- Insomnia
- Mood disorders
- Narcolepsy
- Posttraumatic stress disorder
- Psychosis
- Schizophrenia
- Seasonal affective disorder

Differential Diagnosis

other causes of insomnia
other causes of hypersomnia
psychophysiological insomnia
restless legs syndrome
sleep apnea
- circadian rhythm abnormalities
- periodic limb movement disorders
- posttraumatic stress disorder
- narcolepsy
- daytime somnolence
- schizophrenia
- bipolar hypomania
- idiopathic insomnia
- pain disorders
- prostatic hypertrophy
- nocturnal asthma
- cardiopulmonary disease
- hyperthyroidism
- substance abuse
- inadequate sleep hygiene
- sleep disorders related to psychiatric medication

Also Relevant

Inadequate sleep hygiene
Insomnia
Parasomnias
Posttraumatic sleep disturbance
Rapid eye movement sleep behavior disorder
- Sleep disorders
- Sleep and alcohol use and abuse
- Sleep, trauma, and anxiety
- Sleep and depression
- Sleep terror
- Sleep, trauma, and anxiety

Sleep and mental disorders …

Sleep and mental disorders

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Psychiatric Disorders with Sleep Symptoms

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Telehealth and cognitive behavioral therapy for insomnia (CBT-I)

NonREM parasomnias

Neurologic disorders associated with obesity

Hypersomnolence

Sleep disorders in women

Sleep, stroke, and vascular dementia

Parasomnia overlap disorder and status dissociatus

Stimulant-dependent sleep disorder

Sleep and mental disorders

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Psychiatric Disorders with Sleep Symptoms

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Telehealth and cognitive behavioral therapy for insomnia (CBT-I)

NonREM parasomnias

Neurologic disorders associated with obesity

Hypersomnolence

Sleep disorders in women

Sleep, stroke, and vascular dementia

Parasomnia overlap disorder and status dissociatus

Stimulant-dependent sleep disorder

This is an article preview.
Start a Free Account
to access the full version.